Executive Order 13937: Access to Affordable Life-Saving Medications
President: Donald J. Trump
Directed HHS to require certain health centers to pass through discounted insulin and injectable epinephrine prices to eligible low-income patients through later rulemaking.
Status: Revoked. Is Executive Order 13937 still in effect? No. Executive Order 13937 was revoked. See Federal Register record.
What does Executive Order 13937 do?
HRSA finalized an insulin and epinephrine pass-through rule in December 2020, then rescinded that implementing rule in October 2021 while stating EO 13937 remained in effect.
Evidence review, September 23, 2026: HRSA issued an implementing final rule in December 2020, then rescinded that rule in October 2021. This is a rulemaking outcome, not a finding about the order’s entire present legal effect.
Before and after
Before the order
The 340B program allowed eligible health centers to purchase discounted medicines, while patient charges were governed by other program rules and health-center practices.
After the order
HRSA finalized an insulin and epinephrine pass-through rule in December 2020, then rescinded that implementing rule in October 2021 while stating EO 13937 remained in effect.
The rescission removes the particular 2020 regulatory requirements and explicitly says the executive order remained in effect at that time. It does not establish the order's current legal status or that patients received a specified discount.
Who had to do what
| Agency / official | What the signed order directed | Deadline / timing |
|---|---|---|
| Secretary of Health and Human Services | Condition future section 330(e) grants on health centers offering insulin and injectable epinephrine at their 340B acquisition price plus a minimal administration fee to low-income patients with high cost-sharing, high unmet deductibles or no insurance; determine the low-income criteria. | For future grants; no specific number of days stated. |
Source: Signed Federal Register text.
Later developments
Later authority: HRSA finalized an insulin and epinephrine pass-through rule in December 2020, then rescinded that implementing rule in October 2021 while stating EO 13937 remained in effect. (October 1, 2021)
What happened next
EO 13937 signed.
HRSA finalized an insulin and epinephrine pass-through rule in December 2020, then rescinded that implementing rule in October 2021 while stating EO 13937 remained in effect.
Guide checked against signed order and later official evidence.
Legal and source detail
How it works legally
The rescission removes the particular 2020 regulatory requirements and explicitly says the executive order remained in effect at that time. It does not establish the order's current legal status or that patients received a specified discount.
Sources by type
If a source is unavailable, first check the cited publisher or another official repository. The cited publisher remains the authority.
Primary and official sources
Orders, laws, court records and official implementation material.
How we checked this
Last checked against the sources above on September 26, 2026. How we research →